Wikidata entity: Q2295855
C₃₅H₄₉N₁₁O₉S₂ (P274)
Quantities
| P4250 | defined daily dose | 0.2 |
| P2067 | mass | 831.316 |
| P3780 | active ingredient in | ... | Q29005817 (Eptifibatide Accord) | Eptifibatide Accord |
| P3780 | active ingredient in | ... | Q29006005 (Integrilin) | Integrilin |
| P233 | canonical SMILES | String | C1CC2C(=O)NC(CSSCCC(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)N2C1)CC3=CNC4=CC=CC=C43)CC(=O)O)CCCCN=C(N)N)C(=O)N | ??? |
| P1552 | has characteristic | ... | Q679692 (biopharmaceutical) | biopharmaceutical |
| P366 | has use | ... | Q12140 (medication) | medication |
| P8224 | image of molecular model or crystal lattice model | CommonsMedia | http://commons.wikimedia.org/wiki/Special:FilePath/Eptifibatide%20ball-and-stick.png | ??? |
| P31 | instance of | ... | Q113145171 (type of chemical entity) | type of chemical entity |
| P2017 | isomeric SMILES | String | C1C[C@H]2C(=O)N[C@@H](CSSCCC(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N2C1)CC3=CNC4=CC=CC=C43)CC(=O)O)CCCCN=C(N)N)C(=O)N | ??? |
| P2175 | medical condition treated | ... | Q12152 (myocardial infarction) | myocardial infarction |
| P2175 | medical condition treated | ... | Q188151 (ischemia) | ischemia |
| P2175 | medical condition treated | ... | Q261327 (thrombosis) | thrombosis |
| P2175 | medical condition treated | ... | Q844935 (coronary artery disease) | coronary artery disease |
| P2175 | medical condition treated | ... | Q2032041 (unstable angina) | unstable angina |
| P2175 | medical condition treated | ... | Q18553787 (cerebral artery occlusion) | cerebral artery occlusion |
| P129 | physically interacts with | ... | Q4201964 (Integrin subunit beta 3) | Integrin subunit beta 3 |
| P129 | physically interacts with | ... | Q21107760 (integrin subunit alpha 2b) | integrin subunit alpha 2b |
| P3489 | pregnancy category | ... | Q28123616 (US pregnancy category B) | US pregnancy category B |
| P769 | significant drug interaction | ... | Q45050 (tenoxicam) | tenoxicam |
| P769 | significant drug interaction | ... | Q186969 (ibuprofen) | ibuprofen |
| P769 | significant drug interaction | ... | Q190016 (heparin) | heparin |
| P769 | significant drug interaction | ... | Q244408 (Diclofenac) | Diclofenac |
| P769 | significant drug interaction | ... | Q347941 (parecoxib) | parecoxib |
| P769 | significant drug interaction | ... | Q407617 (sertraline) | sertraline |
| P769 | significant drug interaction | ... | Q408163 (anagrelide) | anagrelide |
| P769 | significant drug interaction | ... | Q408471 (paroxetine) | paroxetine |
| P769 | significant drug interaction | ... | Q408676 (piroxicam) | piroxicam |
| P769 | significant drug interaction | ... | Q408801 (celecoxib) | celecoxib |
| P769 | significant drug interaction | ... | Q409192 ((RS)-ketoprofen) | (RS)-ketoprofen |
| P769 | significant drug interaction | ... | Q409231 (indomethacin) | indomethacin |
| P769 | significant drug interaction | ... | Q409236 (fluvoxamine) | fluvoxamine |
| P769 | significant drug interaction | ... | Q409672 ((RS)-citalopram) | (RS)-citalopram |
| P769 | significant drug interaction | ... | Q411932 ((S)-duloxetine) | (S)-duloxetine |
| P769 | significant drug interaction | ... | Q414028 (meloxicam) | meloxicam |
| P769 | significant drug interaction | ... | Q414462 (apixaban) | apixaban |
| P769 | significant drug interaction | ... | Q419890 ((±)-flurbiprofen) | (±)-flurbiprofen |
| P769 | significant drug interaction | ... | Q420262 (rivaroxaban) | rivaroxaban |
| P769 | significant drug interaction | ... | Q422244 (fluoxetine) | fluoxetine |
| P769 | significant drug interaction | ... | Q425207 (nabumetone) | nabumetone |
| P769 | significant drug interaction | ... | Q481757 (aceclofenac) | aceclofenac |
| P769 | significant drug interaction | ... | Q898407 (venlafaxine) | venlafaxine |
| P769 | significant drug interaction | ... | Q963093 (sulindac) | sulindac |
| P769 | significant drug interaction | ... | Q1215575 (naproxen) | naproxen |
| P769 | significant drug interaction | ... | Q1640947 (phenindione) | phenindione |
| P769 | significant drug interaction | ... | Q1851701 (dalteparin) | dalteparin |
| P769 | significant drug interaction | ... | Q2465218 ((RS)-etodolac) | (RS)-etodolac |
| P769 | significant drug interaction | ... | Q2555245 ((RS)-fenoprofen) | (RS)-fenoprofen |
| P769 | significant drug interaction | ... | Q3563148 (vortioxetine) | vortioxetine |
| P769 | significant drug interaction | ... | Q105969996 (enoxaparin) | enoxaparin |
| P769 | significant drug interaction | ... | Q113368879 (rac-warfarin) | rac-warfarin |
| P769 | significant drug interaction | ... | Q5984881 (ibrutinib) | ibrutinib |
| P769 | significant drug interaction | ... | Q20817252 (tinzaparin) | tinzaparin |
| P769 | significant drug interaction | ... | Q27077698 (fondaparinux) | fondaparinux |
| P769 | significant drug interaction | ... | Q45769835 (alteplase) | alteplase |
| P279 | subclass of | ... | Q126610343 (Integrilin) | Integrilin |
| P2868 | subject has role | ... | Q721432 (platelet aggregation inhibitors) | platelet aggregation inhibitors |
| P2275 | World Health Organisation international non-proprietary name | Monolingualtext | eptifibatide | ??? |
Why not click here or view trends?
log id: 1946375